SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

RUM Group, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

RUM Group Inc. - Ordinary Shares - Class A

RUM Group Inc.

Rumbles Q3 results are driving discussion, with traders highlighting a revenue beat, Quake AI growth and the companys first adjusted-EBITDA profit. The upbeat read is tempered by concerns about cash burn, financing and possible data-center delays, alongside frustration that the stock has not responded more strongly.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeaves quarterly revenue beat and raised outlook, alongside a financing plan centered on customer prepayments rather than new unsecured debt, have fueled a sharp rebound and renewed confidence in AI-compute demand. Traders are also discussing potential short covering, while skeptics argue that heavy debt, interest costs, and capital spending still pose risks to profitability.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

Rigettis disappointing third-quarter results and softer revenue outlook have intensified selling and concerns about its valuation, limited sales, and the long road to commercialization. Traders remain divided: skeptics see weak business traction, while supporters point to quantum-hardware progress and government backing as reasons to take a longer-term view.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Attention centers on the Nov. 22 FDA decision on Capricors deramiocel treatment for Duchenne muscular dystrophy; management reaffirmed confidence on its earnings call and said the application is in final review. Traders are mostly optimistic and focused on launch preparations, but debate remains over the risk of an FDA rejection and the strength of the evidence.

Netlist, Inc. engages in the design, manufacture and sale of memory subsystems for the computing and communications markets. Its products include enterprise SSD, embedded flash, memory module, lightning DDR5 DIMM, SK hynix, AI server. The company was founded by Jayesh Bhakta, Chun Ki Hong and Christopher Lopes in June 2000 and is headquartered in Irvine, CA.

Netlist Inc

Netlists Q3 results and outlook are drawing attention as traders weigh its shift toward recurring licensing revenue under the Samsung and Micron agreements, stronger profitability, and higher expected operating income and product sales in Q4. Many are speculating that SK Hynix could be the next licensing partner, though no new deal is confirmed; others are cautious about the gap between reported results and pre-earnings expectations.

Zcash (ZEC) is a cryptocurrency . Users are able to generate ZEC through the process of mining. Zcash has a current supply of 16,959,453.18587388 with 16,959,453.64420722 in circulation. The last known price of Zcash is 1,033.61575403 USD and is down -11.66 over the last 24 hours. It is currently trading on 670 active market(s) with $1,322,935,861.71 traded over the last 24 hours. More information can be found at https://z.cash/.

Zcash

Zcash is drawing attention for a sharp, volatile selloff, with traders pointing to broader crypto weakness and liquidations while some question why ZEC has fallen harder than the market. The community is split between calling for more downside and treating the drop as a buying opportunity.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidias selloff and volatile rebound are being debated around reports of Jensen Huangs alleged relationship with a China-linked figure and speculation about export-control scrutiny or leadership fallout; traders also point to Bairds downgrade. Bulls argue the controversy does not change Nvidias business and cite CoreWeaves strong results as evidence of continued AI demand, while skeptics remain cautious ahead of Nvidias earnings.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: QNX, Secure Communications, and Licensing. The QNX segment includes development of safe and reliable software for embedded systems across technology-driven industries. The Secure Communications segment delivers operational resiliency with a government-grade portfolio of secure, certified solutions for mobile fortification, critical communications and crisis management. The Licensing segment focuses on management and monetization of the firm's global patent portfolio. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

QNXs collaboration with Valeo on a safety-certified smart-camera platform, which has design wins with multiple Chinese automakers, is drawing attention as traders weigh BlackBerrys expansion in automotive software and other embedded markets. Bulls see the wins and growing backlog as evidence of momentum, while skeptics question how quickly they will translate into revenue and challenge the stocks valuation.

Costco Wholesale Corp. engages in the provision of operation of membership warehouses through wholly owned subsidiaries. It operates through the following geographical segments: United States, Canada, and Other International Operations. The company was founded by James D. Sinegal and Jeffrey H. Brotman in 1983 and is headquartered in Issaquah, WA.

Costco Wholesale Corp

Costcos special dividend and renewed share-buyback authorization are driving attention, with traders celebrating the shareholder payout and many expressing bullish confidence. Some remain cautious about the stocks rich valuation and note that the dividend is not free money, since the share price adjusts when it goes ex-dividend.

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.

Kura Oncology Inc

Kuras Q3 report and earnings call are driving attention, with traders focused on KOMZIFTIs commercial uptake and managements response to competitive J&J AML data. Reactions are mixed: many view the launch and call positively, while others flag competition, bearish put positioning, and possible share issuance as risks.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$SLS So Called BAT - for the SLS Control arm patients has failed 5 Trials in the last year /  
• Aza+Ven has failed to increase survival in 3 phase 3 trials and 2 phase 2&#39;s.  
• All While we are seeing extended near miraculous ALL Pooled Survival in the SLS REGAL Phase 3 
- nearly 40% Survival at 3 years - in a transplant ineligible, Post Salvage AML Second Remission (CR2) Population with a expected MOS of just 6-8 months. 
BAT / Aza+VEN / Onureg + Venclexta FAILED to Increase OS in 5 TRIALS: 
• VERONA Phase 3 $ABBV FAILED high risk MDS/AML Precursor 
• VIALE-M Phase 3 $ABBV FAILED - AML FIRST REMISSION (CR1) 
• VIALE-T Phase 3 $ABBV FAILED - AML Post Transplant Maintenance 
• Opti-AML Phase 2 MDACC Reduced Intensity FAILED 
• Paradigm Phase 2 AML Front Line Modified Dosing again FAILED to Increase Survival.

Kari Lipponen

arturas paulikas

Ari Malaska

Joe Rosenthal

TopOptionsAlerts®

Roger Rabbit $5,56

Kris Kotsay

Janulf

Hemang Patel

Ulaughing

Chessdoc

charles2_01

$SLS On a side note, do bears even know that BAT drugs aren’t approved for AML CR2 ?
There is no approved drug in that setting.

So even when their miracle story of super BAT is coming true, and GPS is doing AS GOOD as BAT (which can’t , cause the trial allready passed futility) ,
There is still a good chance , because of the excellent safety profile , that FDA will approve GPS. 

There is NO bearish case here. NONE

StockTwits for iOS

SELLAS Life Sciences Group Inc

StockTwits Web

Abbvie Inc

 So Called BAT - for the SLS Control arm patients has failed 5 Trials in the last year /  
• Aza+Ven has failed to increase survival in 3 phase 3 trials and 2 phase 2's.  
• All While we are seeing extended near miraculous ALL Pooled Survival in the SLS REGAL Phase 3 
- nearly 40% Survival at 3 years - in a transplant ineligible, Post Salvage AML Second Remission (CR2) Population with a expected MOS of just 6-8 months. 
BAT / Aza+VEN / Onureg + Venclexta FAILED to Increase OS in 5 TRIALS: 
• VERONA Phase 3 

 FAILED high risk MDS/AML Precursor 
• VIALE-M Phase 3 

 FAILED - AML FIRST REMISSION (CR1) 
• VIALE-T Phase 3 

 FAILED - AML Post Transplant Maintenance 
• Opti-AML Phase 2 MDACC Reduced Intensity FAILED 
• Paradigm Phase 2 AML Front Line Modified Dosing again FAILED to Increase Survival.